6-chloro-2-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-chloro-2-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridine
• 英文别名: 1h-Imidazo[4,5-b]pyridine, 6-chloro-2-(3-pyridinyl)-；6-chloro-2-pyridin-3-yl-1H-imidazo[4,5-b]pyridine
• 化学式: C₁₁H₇ClN₄
• mdl: MFCD01364348
• 分子量: 230.656
• InChiKey: HVVOZSJPEUQWMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-吡啶甲醛 、 2,3-二氨基-5-氯吡啶 在 sodium metabisulfite 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以85%的产率得到6-chloro-2-(pyridin-3-yl)-1H-imidazo[4,5-b]pyridine
  参考文献：
  名称：

  Synthesis of 6-chloro-2-Aryl-1H-imidazo[4,5-b]pyridine derivatives: Antidiabetic, antioxidant, β-glucuronidase inhibiton and their molecular docking studies

  摘要：

  6-Chloro-2-Aryl-1H-imidazo[4,5-b]pyridine derivatives 1-26 were synthesized and characterized by various spectroscopic techniques. All these derivatives were evaluated for their antiglycation, antioxidant and beta-glucuronidase potential followed their docking studies. In antiglycation assay, compound 2 (IC50 = 240.10 +/- 2.50 mu M) and 4 (IC50 = 240.30 +/- 2.90 mu M) was found to be most active compound of this series, while compounds 3 (IC50 = 260.10 +/- 2.50 mu M), 6 (IC50 = 290.60 +/- 3.60 mu M), 13 (IC50 = 288.20 +/- 3.00 mu M) and 26 (IC50 = 292.10 +/- 3.20 mu M) also showed better activities than the standard rutin (IC50 = 294.50 +/- 1.50 mu M). In antioxidant assay, compound 1 (IC50 = 69.45 +/- 0.25 mu M), 2 (IC50 = 58.10 +/- 2.50 mu M), 3 (IC50 = 74.25 +/- 1.10 mu M), and 4 (IC50 = 72.50 +/- 3.30 mu M) showed good activities. In beta-glucuronidase activity, compounds 3 (IC50 = 29.25 +/- 0.50 mu M), compound 1 (IC50= 30.10 +/- 0.60 mu M) and compound 4 (IC50 = 46.10 +/- 1.10 mu M) showed a significant activity as compared to than standard D-Saccharic acid 1,4-lactonec (IC50 = 48.50 +/- 1.25 mu M) and their interaction with the enzyme was confirm by docking studies. (C) 2016 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.bioorg.2016.01.007

文献信息

• CASEIN KINASE 1DELTA (CK1DELTA) INHIBITORS
  申请人：Electrophoretics Limited

  公开号：EP2651404B1

  公开（公告）日：2015-10-14
• CASEIN KINASE 1DELTA (CK 1DELTA) INHIBITORS
  申请人：Sheridan Joseph M.

  公开号：US20140018540A1

  公开（公告）日：2014-01-16

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES
  申请人：Electrophoretics Limited

  公开号：US20160354375A1

  公开（公告）日：2016-12-08

  The invention relates to pharmaceutical compositions comprising casein kinase 1 delta (CK1δ) and to the use of said inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
• US9763947B2
  申请人：——

  公开号：US9763947B2

  公开（公告）日：2017-09-19
• US9789111B2
  申请人：——

  公开号：US9789111B2

  公开（公告）日：2017-10-17